arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Phathom Pharmaceuticals, Inc.

PHAT

$5.07 ▼ -0.62 (-10.90%) at close

9 Visible periods

29 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Fair

Neutral

auto_awesome

Analytical Summary

Phathom Pharmaceuticals, Inc. demonstrates solid fundamentals with strength in Return on Common Equity (%). Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $369.7M

Dividend Yield —

Revenue Growth 216.9% ↘

Op. Margin -91.4%

ROIC 69.8% ↘

FCF / Share $-2.29 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity -0.48

info Valuation on last close. End-of-day price, Nov 5, 2026.

9-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$175.11M

↑ +216.9% —

Net Income Profit after all expenses

$-221.25M

↑ +33.8% —

FCF / Share Free cash flow per share

$-2.29

↑ +45.8% —

Long-Term Debt Long-term obligations

$209.09M

↑ +3.8% —

trending_up

Bullish Indicators

Debt to EquityDebt to Equity is in the top quartile (lower is better)
Return on Common Equity (%)Return on Common Equity (%) is in the top quartile

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑

Returns

Financial Health ↑

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Revenue Growth YoY (%)	216.9% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+2612%)	8001.5% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+99918%)	—	—	—	—	—	—	—
EPS Growth YoY (%)	42.7% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-34.6% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	22.2% Good Good Year-over-year change in earnings per share Optimal: > 10%	-29.8% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	33.8% Excellent ↑ Excellent Improving Year-over-year change in net income	-65.8% Weak ↓ Weak Declining Year-over-year change in net income	-2.0% Weak ↓ Weak Declining Year-over-year change in net income	-37.4% Weak ↑ Weak Improving Year-over-year change in net income	-11.5% Weak ↑ Weak Improving Year-over-year change in net income	49.4% Excellent Excellent Year-over-year change in net income	-19708.3% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	45.8% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-55.6% Weak ↓ Weak Declining Year-over-year change in free cash flow	28.0% Excellent Excellent Year-over-year change in free cash flow	6.2% Fair Fair Year-over-year change in free cash flow	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Operating Margin (%) (%)	-91.4% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-709%)	—	—	—	—	—	—	—	—
Effective Tax Rate (%) (%)	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—	—	—
Profit Margin (%) (%)	-126.3% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1153%)	—	—	—	—	—	—	—	—
FCF Margin (%) (%)	-95.4% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-483.1% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—	—	—
FCF / Net Income (x)	0.75x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.69x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.75x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	1.03x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.55x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.14x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.79x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Return on Invested Capital (%)	69.8% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	531.8% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-203.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-666.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-65.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-41.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-33.5% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	75.3% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-61.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-73.3% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-40.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-104.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-71.3% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-42.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-41.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	-135.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	50.5% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+237%)	131.8% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+779%)	277.1% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1747%)	264.3% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1662%)	-199.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1429%)	-66.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-543%)	-111.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-846%)	100.2% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+568%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Debt to Equity (x)	-0.48x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-180%)	-0.79x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-232%)	-1.89x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-416%)	-1.27x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-312%)	1.24x Caution ↑ Caution Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+107%)	0.24x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-60%)	0.10x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-83%)	—	—
Interest Coverage (x)	-7.49x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-16.05x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-3.99x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-6.32x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-19.90x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-27.43x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-25.43x Weak Weak Operating income divided by interest expense Optimal: > 5x	-94.23x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$79.11M	$-95.85M	$-243.55M	$-60.12M	$-93.59M	$-240.51M	$-220.99M	$-879.00K	—
Debt / EBITDA (x)	-1.31x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.73x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.83x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.55x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.67x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.37x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.21x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Revenue per Share (USD)	$2.40	$0.87	$0.01	$0.00	—	—	—	—	—
Basic EPS, GAAP (USD)	$-3.03	$-5.29	$-3.93	$-5.05	$-3.89	—	—	—	—
Free Cash Flow per Share (USD)	$-2.29	$-4.22	$-2.71	$-3.77	$-4.02	—	—	—	—
Book Value per Share (USD)	$-6.14	$-3.70	$-1.26	$-1.80	$2.36	$6.81	$9.22	—	—
Tangible Book Value per Share (USD)	$-6.14	$-3.70	$-1.26	$-1.80	$2.36	$6.81	$9.22	—	—
Basic Weighted Avg Shares (shares)	72.92M	63.18M	51.29M	39.12M	37.00M	—	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Working Capital (USD)	$96.93M	$274.41M	$358.65M	$134.28M	$167.60M	$235.84M	$251.85M	$-1.29M	—
LT Debt (USD)	$209.09M	$201.41M	$137.84M	$95.26M	$89.67M	$46.99M	$22.78M	—	—
Total Equity (USD)	$-438.17M	$-253.58M	$-72.76M	$-74.81M	$72.16M	$194.27M	$227.96M	$-1.29M	$0.00

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Sales/Revenue/Turnover (USD)	$175.11M	$55.25M	$682.00K	$0.00	—	—	—	—	—
Depreciation Expense (USD)	$633.00K	$795.00K	$575.00K	$620.00K	$521.00K	$323.00K	$8.00K	$0.00	—
Net Income, GAAP (USD)	$-221.25M	$-334.33M	$-201.59M	$-197.72M	$-143.88M	$-129.07M	$-255.13M	$-1.29M	—
Operating Cash Flow (USD)	$-166.78M	$-266.77M	$-137.58M	$-146.53M	$-148.46M	$-69.69M	$-36.51M	$-1.02M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 9 years · 36 quarters

Phathom Pharmaceuticals, Inc.

Analytical Summary

9-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare PHAT with peers